Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
421-440 of 1,694 trials

Juvenile Idiopathic Arthritis: Filgotinib Study

We are studying how the medication filgotinib works in children and teens with juvenile idiopathic arthritis. The trial will also evaluate its safety and how well young patients accept the medication.

Juvenile Idiopathic Arthritis≤3 monthsSafety phase (I)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPediatricsRheumatology

HIV Treatment: Doravirine/Tenofovir/Lamivudine Study

We are studying a combination of medications for people living with HIV who have a history of specific mutations. The goal is to see if this treatment helps maintain viral control and improves health over time.

HIV Disease1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Acute Myeloid Leukemia: DASATINIB Treatment Study

We are evaluating the effectiveness of DASATINIB for patients with acute myeloid leukemia who did not respond to previous treatments. The study aims to see if this medication can help reduce tumors and identify factors that predict response.

Acute Myeloid Leukemia≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Chronic Pain Prevention: Duloxetine for Hernia Surgery

We are studying whether duloxetine can help prevent chronic pain in patients at high risk after inguinal hernia repair. We will also compare its safety to a placebo.

Chronic Pain After Surgery3-6 monthsConfirmation phase (III)Investigational MedicinesPartially RemoteInternal MedicineNeurologyOrthopedics and Traumatology

Lung Cancer: Enhanced Skin Care Management

We are studying if improved skin care can help reduce skin side effects in patients with advanced EGFR-mutated lung cancer receiving amivantamab and lazertinib. This trial compares enhanced care to standard skin management.

EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer≤3 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteDermatologyOncology

Colchicine for Heart and Kidney Health in Chronic Kidney Disease

We are studying whether low-dose colchicine can help prevent heart problems and slow kidney disease in people with moderate chronic kidney disease. This trial will also look at the safety of the treatment and its effects on inflammation.

Chronic Kidney Disease>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesCardiologyNephrology

Breast Cancer Treatment: OP-1250 vs Standard Care

We are studying a new medication, OP-1250, for people with advanced or metastatic ER+, HER2- breast cancer. The goal is to see if it is safer and more effective than current standard treatments.

Estrogen Receptor Positive Breast CancerConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Stem Cell Transplantation vs. Immunosuppressive Therapy for Systemic Sclerosis

We are studying whether upfront stem cell transplantation is more effective than immunosuppressive medication for early diffuse cutaneous systemic sclerosis. This trial will help us understand the best treatment approach for improving survival and quality of life.

Diffuse Cutaneous Systemic SclerosisMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesRheumatology

Metastatic Castration-Resistant Prostate Cancer: Gedatolisib and Darolutamide Study

We are studying a new combination of gedatolisib and darolutamide for men with metastatic castration-resistant prostate cancer. The trial will evaluate safety, tolerability, and how well this treatment works.

Castration-Resistant Prostate Cancer1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncologyUrology

Acute Myeloid Leukemia: Personalized Treatment Based on FLT3 Mutation

We are studying a new treatment strategy for patients with FLT3-positive AML, using a biomarker to tailor therapy. The goal is to see if this approach improves survival compared to standard treatments.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

Acute Myeloid Leukemia: RVU120 with Venetoclax

We are studying a new treatment combining RVU120 and Venetoclax for patients with acute myeloid leukemia who did not respond to earlier therapies. The goal is to assess its safety and effectiveness in improving their condition.

Acute Myeloid Leukemia6-12 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Allergy Relief: Sublingual Immunotherapy for House Dust Mite Allergies

We are studying a new treatment for individuals aged 12-65 with rhinitis or asthma caused by house dust mites. The goal is to see if this therapy can improve allergy symptoms compared to a placebo.

Allergic Rhinitis and Asthma1-2 yearsConfirmation phase (III)Investigational MedicinesAllergologyPulmonology

IgM Monoclonal Gammopathy: Zanubrutinib and Rituximab Study

We are investigating whether a new treatment combining Zanubrutinib with Rituximab can improve nerve function in patients with IgM monoclonal gammopathy and related nerve damage. The study will also look at safety and how well patients tolerate the treatment.

Anti-MAG Neuropathy>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyNeurology

Type 2 Diabetes: Semaglutide for Bone Health

We are investigating whether oral Semaglutide can improve bone formation and strength in men and women with type 2 diabetes. This study focuses on those with normal or low bone mass.

Type 2 Diabetes1-2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementDiabetologyEndocrinologyRheumatology

Persistent Atrial Fibrillation: Cryoballoon vs. Medication

We are studying whether early treatment with a cryoballoon is more effective than antiarrhythmic drugs for people with persistent atrial fibrillation. The trial also looks at how these treatments affect quality of life and healthcare needs.

Persistent Symptomatic Atrial Fibrillation>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiology

Anal Cancer Treatment: Induction Chemotherapy Study

We are studying a new treatment approach for locally advanced anal squamous cell carcinoma to see if adding induction chemotherapy improves outcomes compared to standard treatment. This trial will help us understand its effects on survival and quality of life.

Locally Advanced Anal Squamous Cell CarcinomaConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

High-Risk Aggressive B-Cell Lymphomas: R-Hyper-CVAD/R-MA Treatment

We are studying a new treatment approach for patients with high-risk aggressive B-cell lymphomas to see if it is effective and safe. This trial aims to improve outcomes for those facing this serious condition.

Lymphoma3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

DIPG Treatment Study: ONC201 vs. Everolimus

We are testing a new drug, ONC201, for children with newly diagnosed DIPG and related tumors. The goal is to see if it helps improve survival and progression-free time compared to standard treatment.

Brain Stem Glioma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesOncologyPediatrics

Follicular Lymphoma: Mosunetuzumab and Zanubrutinib Study

We are investigating a combination of two medications for patients with relapsed or refractory follicular lymphoma. The goal is to see if this treatment improves outcomes and safety compared to existing options.

Follicular Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematology

Colorectal Cancer: Reduced Dose Chemotherapy for Older Patients

We are studying whether a lower dose of chemotherapy is as effective as the standard dose for older patients with advanced colorectal cancer. This may help improve quality of life and reduce severe side effects.

Metastatic Colorectal Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology